Filing Details

Accession Number:
0001209191-15-019812
Form Type:
4
Zero Holdings:
No
Publication Time:
2015-02-27 18:01:13
Reporting Period:
2015-02-20
Filing Date:
2015-02-27
Accepted Time:
2015-02-27 18:01:13
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1103021 Biodelivery Sciences International Inc BDSI Pharmaceutical Preparations (2834) 352089858
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1301715 A Mark Sirgo C/O Biodelivery Sciences Intl, Inc.,
4131 Parklake Avenue, Suite 225
Raleigh NC 27612
President And Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2015-02-20 140,000 $0.00 1,059,800 No 4 M Direct
Common Stock Acquisiton 2015-02-22 96,837 $0.00 1,156,637 No 4 M Direct
Common Stock Disposition 2015-02-25 94,000 $14.25 1,062,637 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Units Disposition 2015-02-20 140,000 $0.00 140,000 $0.00
Common Stock Restricted Stock Units Disposition 2015-02-22 96,837 $0.00 96,837 $0.00
Common Stock Restricted Stock Units Acquisiton 2015-02-23 800,000 $0.00 800,000 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
140,000 2015-02-20 2016-02-20 No 4 M Direct
193,674 2015-02-22 2017-02-22 No 4 M Direct
800,000 2018-02-23 No 4 A Direct
Footnotes
  1. The shares of common stock were acquired by the Reporting Person as a result of the vesting of 140,000 Restricted Stock Units ("RSUs") granted to the Reporting Person on February 20, 2013 under the Issuer's 2011 Equity Incentive Plan, as amended. The remaining RSUs under this grant will vest on February 20, 2016.
  2. The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs granted to the Reporting Person on February 22, 2014 under the Issuer's 2011 Equity Incentive Plan, as amended. One-third of the RSUs under this grant will vest on each of, (i) February 22, 2016 and (ii) February 22, 2017.
  3. The shares of common stock were sold under a pre-planned 10b5-1 trading plan, and were sold to cover the Reporting Person's tax liability upon the vesting of RSUs.
  4. On February 25, 2015, the Reporting Person sold an aggregate of 94,000 shares of the Issuer's Common Stock at a weighted average price of $14.25. The highest sale price for the Common Stock was $14.62 per share and the lowest sale price was $13.90 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  5. The RSUs were issued to the Reporting Person on February 23, 2015, pursuant to a grant under the Issuer's 2011 Equity Incentive Plan, as amended. One-third of the RSUs will vest on each of, (i) February 23, 2016, (ii) February 23, 2017 and (iii) February 23, 2018. Upon vesting, each RSU entitles the Reporting Person to one share of the Issuer's common stock.